Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05739136 · ClinicalTrials.gov registry record
MYFEMBREE®: A Retrospective Cohort Study Using an Administrative Healthcare Database to Assess Pregnancy Outcomes in Women Treated With Relugolix Combination Therapy
A clinical trial of Pregnancy Related and Pregnancy Complications, sponsored by Sumitomo Pharma Switzerland.
- Active
- Registry status
- 530
- Enrollment target
- 1
- Study location
NCT05739136: Active study of Pregnancy Related and Pregnancy Complications, sponsored by Sumitomo Pharma Switzerland.
NCT05739136 is a study of Pregnancy Related and Pregnancy Complications that is active but no longer recruiting, run by Sumitomo Pharma Switzerland. The registered enrollment target is 530 participants, below the 1,958-participant average among 99 other Pregnancy Related trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05739136, a study of Pregnancy Related and Pregnancy Complications, is active but no longer recruiting, sponsored by Sumitomo Pharma Switzerland.
- ACTIVE NOT RECRUITING
- Registry status
- 530 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a retrospective cohort study that will be conducted using secondary de-identified electronic healthcare data (EHD) that originally were collected for the purposes of health insurance billing and/or routine patient care from healthcare providers (HCPs). The study is designed to evaluate the association between relugolix combination therapy (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) exposure during pregnancy and subsequent fetal and infant outcomes.
Primary Outcome
Comparison of rate of MCM between cohorts
Conditions Studied
Interventions
- DRUG Relugolix + Estradiol + Norethindrone Acetate
Study Locations (1)
Massachusetts
- SMPA - Marlborough
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 530 participants |
| Start Date | 2025-04-30 |
| Est. Completion | 2027-05 |
What the registry record for NCT05739136 still lists
NCT05739136 is an observational study that tracks outcomes without assigning an intervention. The registered 530 participants enrollment target is mid-sized for trials with a published cap, below the 1,958-participant average among 99 other Pregnancy Related trials with a reported enrollment target (73% lower).
The record links to 3 conditions, with Pregnancy Related appearing as the primary indexed condition, and to 1 intervention - of which Relugolix + Estradiol + Norethindrone Acetate is the first listed.
NCT05739136 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05739136 about?
NCT05739136 is a clinical study titled "MYFEMBREE®: A Retrospective Cohort Study Using an Administrative Healthcare Database to Assess Pregnancy Outcomes in Women Treated With Relugolix Combination Therapy". This is a retrospective cohort study that will be conducted using secondary de-identified electronic healthcare data (EHD) that originally were collected for the purposes of health insurance billing and/or routine patient care from healthcare providers (HCPs). The study is designed to evaluate the a...
What is the current status of trial NCT05739136?
This trial is currently active not recruiting. The enrollment target is 530 participants. The study started on 2025-04-30. Estimated completion is 2027-05.
What conditions does trial NCT05739136 study?
This clinical trial studies the following conditions: Pregnancy Related, Pregnancy Complications, Pregnancy, High Risk.
What interventions are being tested in trial NCT05739136?
The interventions under investigation include: Relugolix + Estradiol + Norethindrone Acetate (DRUG).
Who is sponsoring clinical trial NCT05739136?
This trial is sponsored by Sumitomo Pharma Switzerland, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05739136 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pregnancy Related
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05739136's enrollment target sits among peer trials
530 28th of 99 higher than 72 of 99 other Pregnancy Related trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pregnancy Related trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Antenatal Support for Iron Deficiency Anemia
RECRUITING · Phase 4
-
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis
RECRUITING
-
Mobile Application-based Exercise Intervention for Pregnant Women
RECRUITING · NA
-
Rigorous Evaluation of Yes and Know, a Fully Virtual Sexual Health and Well-Being Intervention for Youth
RECRUITING · NA
-
Physiological-based Pharmacokinetics Approach to Medication Exposure During Pregnancy and Breastfeeding
RECRUITING
-
Resources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06646276 · 530 participants · Phase 3
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
- NCT06703476 · 530 participants · Phase 3
A Study of Surgical Techniques During Cystectomy
- NCT06880744 · 530 participants · Phase 3
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
- NCT07138040 · 530 participants · NA
Re-Engaging AYA Survivors in Cancer-Related Healthcare
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI